7%: 109
More serious side effects may include pancreatitis, kidney issues and thyroid tumors
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities
Related Reading Medvi Semaglutide Bioverse Semaglutide Ro Semaglutide Mochi Semaglutide Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims
Most people find that side effects are manageable within two to four weeks of restarting
Patient 2 The patient is a 44-year-old woman with a history of major depressive disorder, attention-deficit/ hyperactivity disorder, generalized anxiety disorder, and obesity